Bernstein Moves Alnylam to Market Perform Over Nucresiran Trial Concerns
Photo: TokenPost
Bernstein shifted its rating on Alnylam Pharmaceuticals on Friday, Oct. 30, from Outperform to Market Perform, citing concerns about the design of TRITON-CM, a Phase 3 study of nucresiran. Analyst Jeffrey Walch was behind the rating action. Nucresiran is Alnylam's next-generation RNAi therapeutic. Enna Lee reports on investing and digital-asset markets for TokenPost. Send corrections or tips to info@tokenpost.com.
Source: TokenPost
